DocGo Inc. (DCGO) is a New York-based provider of technology-enabled mobile health services and medical transportation, operating ambulance and non-emergency transport fleets alongside mobile phlebotomy, remote patient monitoring and virtual care through a 50-state clinician network. The company serves municipalities, hospital systems and insurers, and generates roughly $300 million in annual revenue.
In Monday's session, the stock traded at $0.1888, a decline of $0.0188, or 9.06%, from the prior close of $0.2076. The direction is unambiguously negative, and the price marks a fresh 52-week low for the micro-cap, whose market capitalization has slipped to roughly $19 million. No verified catalyst specific to Monday's session was found; the move extends a downtrend that accelerated after the company's third-quarter report.
No verified news or fundamental catalyst found for Monday's trading. No regulatory filing, financing announcement, contract loss or analyst revision accompanied the decline. The most defensible reading is that the selling is a continuation of the post-earnings repricing that began on Nov. 9, reinforced by the mechanics of a sub-$1, thinly traded equity.
Impulse and momentum effects are consistent with the evidence: the shares have now fallen in four of the last five sessions, dropping from $0.2518 on Nov. 9 to $0.1888, a loss of about 25%. For a stock this small, quoted spreads are wide and order books shallow, so modest sell interest can produce outsized percentage moves without any new information.
The fundamental backdrop remains the November quarter. DocGo reported revenue of $73.4 million, up 3.7% year over year but below consensus of roughly $77 million, and a GAAP net loss of $0.17 per share against an expected loss of about $0.04. Management trimmed 2026 revenue guidance to approximately $300 million from $305–$310 million, citing the deliberate elimination of unprofitable contracts, while reaffirming a full-year adjusted EBITDA loss of $17–$22 million.
The company also disclosed that chief executive Lee Bienstock will step down once a successor is named, with his contract expiring Dec. 31 and an executive search underway. One sell-side firm cut its price target to $1 from $3 while keeping a Buy rating, citing the guidance reduction and the leadership change. With unrestricted cash of $19.1 million at quarter-end and a fresh $12.5 million debt tranche drawn in October, the market's focus has shifted decisively from growth to runway.
The shares have traded below $1 since early 2026, keeping the company exposed to Nasdaq's minimum bid-price requirement and the possibility of a reverse split or other remedial step. Adding to the uncertainty is the pending acquisition of virtual-care provider Hicuity Health, expected to close in late November or early December and excluded from current guidance. Investors are weighing whether the deal adds scale or leverage, and each session without resolution has tended to favor sellers.
Volume in the name has been running above its longer-run norm: the 30-day average is roughly 700,000 shares versus about 514,000 across the last 60 sessions, a pattern typical of heavy liquidation in a falling micro-cap. The move diverged from broad healthcare and transport benchmarks, which is consistent with company-specific selling rather than sector rotation.
Technically, the picture is weak. The stock is roughly 40% below its 50-day moving average and about 65% below its 200-day average, with Monday's price undercutting the prior 52-week floor of $0.207. There is no nearby support level of consequence from recent trading, and the shares are down more than 80% over twelve months.
The score runs from 0, meaning no meaningful news and an ordinary move for the stock, to 100, meaning transformative news and an extreme, rare price move. DocGo's score is 30 out of 100.
The verified news is real but not new: an earnings miss, a guidance cut, a CEO transition and a reduced price target amount to moderate-to-material news for a company of this size, though the market has had a week to digest it. The price move was about 2.2 times the stock's typical absolute daily move of roughly 4% over the last 60 sessions, and swings of this magnitude occurred six times in that window. Familiar volatility and stale news combine into a modest score.
Attention now turns to the Hicuity Health closing and whether the combined business delivers the promised revenue contribution in 2027. Fourth-quarter results, expected in March, will be scrutinized for evidence that the adjusted EBITDA loss closes toward breakeven after the $3.2 million third-quarter shortfall, and for cash burn after the October financing. The board's CEO search remains an open variable, as does any Nasdaq compliance update. Risks include further contract exits, margin pressure in mobile health, delayed deal closing and the possibility that liquidity becomes the dominant narrative. Analysts currently carry a Buy consensus, though targets remain far above the market price.
Tickeron's Trending AI Robots page curates the strongest automated strategies operating in current market conditions, drawn from a library of hundreds of AI trading bots that cover thousands of tickers. Bots differ widely by strategy logic, holding timeframe, performance metrics and the symbols they trade, so the featured list changes as conditions shift. It is a practical starting point for investors who want to see which automated approaches are working right now — worth a look alongside your own research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCGO advanced for three days, in 186 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
DCGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DCGO as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for DCGO turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DCGO entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.204) is normal, around the industry mean (204.532). P/E Ratio (-0.126) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.127) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. DCGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DCGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement